CRISPR Therapeutics AG
CRSP
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
100.9% downsideOvervalued by 100.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.42 Billion |
|---|---|
| Enterprise Value | $5.80 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.47 |
| Beta | 1.74 |
| Outstanding Shares | 96,051,228 |
Return
| Return on Equity | -31.33% |
|---|---|
| Return on Assets | -20.86% |
| Return on Invested Capital | -23.10% |
Valuation & Multiples
| P/E Ratio | -9.49 |
|---|---|
| PEG | 98.8 |
| Price to Sales | - |
| Price to Book Ratio | 2.89 |
| Enterprise Value to Revenue | 1413.15 |
| Enterprise Value to EBIT | -9.69 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8378▲ 6.57% |
|---|---|
| Total Calls | 2,090,370▼ 34.71% |
| Total Puts | 1,751,400▼ 29.16% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 85.79%▲ 0.70% |
|---|---|
| Total Invested | $3.67B▼ 8.60% |
| Investors Holding | 521▲ 2.00% |
ESG Score
No data
About CRISPR Therapeutics AG
CEO: Samarth Kulkarni Relevant Senate Committees
This committee provides the crucial 'revenue estimates' and technical analysis for all tax legislation, directly shaping corporate tax structures, capital investment incentives, and the overall tax burden that significantly impacts CRSP's financial planning and valuation.
This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy directly impact CRSP's profitability, and its influence over Medicare pricing significantly affects future revenue streams for therapeutic products.
This committee allocates discretionary federal spending. Its subcommittees determine the precise funding for scientific research (e.g., NIH), which directly impacts the R&D ecosystem and potential grants crucial for biotech innovation and development.
This committee directly regulates the FDA, whose approval is essential for CRSP's biological products, and the NIH, a major source of research funding. It is a primary regulatory body for the pharmaceutical and biotech sectors.
Intellectual property (patents) is foundational for a gene-editing company like CRSP. This committee's oversight of antitrust laws and IP is critical, directly influencing CRSP's ability to protect its innovations and engage in potential M&A activities.